Mechanisms of thrombocytopenia were studied in 38 patients with mild to moderately severe chronic autoimmune thrombocytopenia (AITP). 5"Cr and "'In-labeled autologous platelet turnover studies and in vitro analysis of committed megakaryocyte progenitors (CFU-Meg) were used as independent measures of platelet production. Autologous "'In-labeled platelet localization studies were performed to assess platelet clearance.
Introduction
Autoimmune thrombocytopenic purpura (AITP)' is a disorder characterized by thrombocytopenia, increased levels ofplateletassociated immunoglobulin and normal to increased numbers of marrow megakaryocytes (1) (2) (3) . In studies of patients with acute AITP, a markedly shortened platelet survival and increased platelet turnover have been the accepted kinetic parameters of this condition (4, 5) . Several investigators have described a close correlation between the circulating platelet count and platelet survival (6) (7) (8) (9) , suggesting thrombocytopenia results from accelerated peripheral destruction of platelets. However, autologous platelet turnover studies in 25 patients with chronic AITP showed that platelet production was decreased in a significant number (10).
Platelet antibody tests. Levels of platelet-associated IgG, IgM, or C3 were determined using a '25I-radiolabeled platelet antiglobulin assay similar to that described by Cines and Schreiber (24). An F(ab%2 fraction of rabbit anti-human IgG and an anti-human IgM antibody were prepared by established techniques (25, 26) . Standardization ofanti-human IgG was performed using an "'I-labeled IgG PLAO alloantibody (27) .
Goat anti-human C3 was obtained from Atlantic Antibodies, Scarborough, ME, and used as the complete Ig. "'2I-labeling of antibodies to IgG, IgM, and C3 reagents were performed by the chloramine-T method (28) . Platelet-rich plasma was obtained by centrifugation of peripheral blood collected in EDTA (10%) at 200 g for 9 min. Unbound Ig was removed' from the platelets by passage over a sepharose 2B-CL column (equilibrated in Tris-buffered saline, pH 7.0) (29). The platelet eluate was collected and counted. A calibrated amount of _'I-F(ab')2 rabbit anti-human IgG was added to 108 platelets, and the mixture was incubated at 370C for 30 min. The plateletes were then washed three times in phosphate-buffered saline/bovine serum albumin (1.6%) buffer with centrifugation at 2,000 g for 10 min. The radioactivity of the platelet button was determined with a gamma spectrometer and the result for the patient's platelets was compared with simultaneously analyzed normal control platelets. When the value for the control platelets fell within our normal range (< 3.6 fg IgG/platelet), the absolute quantity ofIgG bound per platelet for patient specimens was calculated. In those cases where the concurrent control results varied above our established normal range, we were able to assess the presence of increased IgG relative to the concurrent control, but an absolute quantitation was considered unreliable. Detection ofplatelet-associated IgM and C3 was performed in an identical manner, but absolute quantitation was not done. Normal ranges for platelet-associated IgM or C3 were established on a daily basis by concurrently run normal control samples. Abnormal results were considered to be > 2 SD from control values.
Assay ofhematopoietic progenitors. Megakaryopytic and granulocytemacrophage colony-forming cells (CFU-Meg and CFU-GM, respectively) were assayed in methylcellujose as previously described (30) . Heparinized iliac crest marrow aspirates were diluted two-to threefold in Hanks' balanced salt solution (HBSS, Gibco, Grand Island, NY). Low-density mononuclear cells were obtained by centrifugation of the marrow cells at 1,500 g for 20 min at room temperature on Ficoll-diatrizoate (1.077 gm/ml; LSM, Litton Bionetics, Kensington, MD). The mononuclear cell fraction at the interface was washed three times in HBSS and suspended to a final concentration of 10' cells/ml in Iscove's Modified Dulbecco's Medium (Gibco) made semisolid with 0.9% methylcellulose and supplemented with 25% human plasma, 5% phytohemagglutinin-stimulated lymphocyte conditioned medium, 5 X 10-' M B-mercaptoethanol, 10 mM L-glutamine, and penicillin-streptomycin. All studies were performed with plasma from the same normal donor. The cell suspension was dispensed in l-ml volumes into 35-mm plastic tissue culture dishes (Lux, Miles Laboratories Inc., Naperville, IL). The cultures were incubated at 370C in a high-humidity 5% CO2-95% air mixture for 13 d.
Megakaryocyte and granulocyte-macrophage colonies were enumerated by examination with an inverted microscope using previously described criteria (30) . Early erythroid progenitors (BFU-E) were assayed concomitantly as previously described (31 
In vivo studies
Platelet kinetic studies. All survival studies were performed with autologous platelets at a time when the platelet count was stable. Platelet turnover was calculated by the formula: turnover = (platelet count/,ul X 90%)/platelet survival (d) X % recovery. At stable platelet counts, platelet turnover = platelet production = platelet destruction (33) .
In the patients with platelet counts > 20 X 109/liter, platelet survival studies were performed with "Cr and/or "'In-labeled platelets. Those patients with counts < 20 X 109/liter were studied exclusively with l'Inlabeled platelets. Women of childbearing age were excluded from "'Inlabeled platelet studies. "Cr-labeled platelet survival was measured according to the method ofHarker and Finch (33) . "'In-oxine (Mediphysics, Emeryville, CA or Chicago, IL) platelet survivals were performed using a closed bag modification of Thakur et al. (34) as previously described (35) . Venous samples for determining platelet radioactivity following platelet injection were drawn at 0.5, 1, and 4 h on day 1, twice daily on days 2 and 3, and daily on days 4, 5, and 6. Platelet survival was calculated by computer-assisted analysis ofthe radioactive decay (gamma function analysis) (36 
Results
Platelet counts. Platelet counts for patients in each treatment group are shown in Fig. 1 . Two patients, both in the "no treatment" group, had platelet counts too low (4 and 11 X 109/liter) to perform autologous platelet kinetic or antibody studies. Platelet counts averaged 78±47 X 109/liter, 96±54 X 109/liter, and 212±250 X 109/liter, respectively, in the no treatment, prednisone-treated, and postsplenectomy groups.
Assays of hematopoietic progenitors. Marrow culture data were not available for 15 patients who declined a repeat bone marrow aspiration on referral to the study. Assays for CFU-Meg were performed on 29 occasions on 23 patients. BFU-E and CFU-GM were assayed concurrently to determine whether any observed changes in CFU-Meg were specific. As shown in Table  I , the frequencies of CFU-Meg, BFU-E, and CFU-GM in the untreated, prednisone-treated, the splenectomized groups did not differ significantly from normal or from each other. Meg in the splenectomized patients was not significantly different from normal. The cycling activity of BFU-E and CFU-GM in the three treatment groups was not changed from normal. When the CFR-Meg cell cycle kinetics was correlated with the peripheral platelet count rate for all patients (Fig. 2) , a significant inverse correlation was found (r = -0.65; P < 0.001). However, for the patients with platelet counts < 170 X 109/liter at the time ofstudy, there was no significant relationship between these two parameters despite a mean suicide rate (62%±17; P < 0.01) that was significantly higher than the normal controls.
Autologous platelet survival studies. Autologous platelet survivals were all less than normal with the exception of two postsplenectomy patients. Furthermore, 36 of the 44 survivals performed were disproportionately reduced for their platelet count (37) . Platelets were cleared exponentially in most patients and survival curves were never multiphasic. There was a significant correlation (r = 0.64; P < 0.00 1) between the platelet count and platelet survival when all patients were included ( Fig. 3 ). However, when analyzed by treatment group, only the splenectomized patients showed a significant correlation between these two parameters (r = 0.84; P < 0.001). Furthermore, if only the 36 patients with platelet counts of < 170 X 109/liter were analyzed, There was a significant, direct correlation (r = 0.68; P < 0.001) between log platelet count and platelet turnover for all patients, and this correlation remained significant for the thrombocytopenic patients (r = 0.63; P < 0.001) (Fig. 4) . Autologous "'In platelet localization studies. In both the untreated and prednisone-treated patients, the average liverspleen uptake ofautologous platelets was significantly increased compared with control values but not from each other (Table  IV) . This increase was due to increased splenic sequestration as there was no significant increase in liver sequestration in untreated (13%±4) or prednisone-treated patients (1 1%±4) compared with controls (14%±2). In contrast, patients in the splenectomized groups had significantly increased liver activity (41%±13) compared with controls (P < 0.001) and untreated (P < 0.001) and prednisone-treated (P < 0.005) patients. However, there was a significant disparity in the mean clearance rates when the postsplenectomy patients were subdivided into treatment responders and nonresponders. The four patients who failed splenectomy showed significantly higher mean clearance rates (P < 0.01) than the total normal spleen-liver clearance, whereas those patients who responded had clearance rates significantly below normal (P < 0.005) (Table IV) .
Production/clearance index. The contribution ofboth platelet production and spleen-liver platelet clearance to the platelet count was best expressed by an index relating platelet production to RE clearance: index = platelet turnover (expressed as a fraction ofnormal)/spleen-liver clearance (expressed as a fraction ofnormal). As shown in Fig. 5 , there was a significant correlation between the production/clearance index and the circulating platelet count when all patients were included (r = 0.88; P < 0.001). In addition, this correlation remained significant when the thrombocytopenic patients were analyzed separately (r = 0.78; P < 0.001). Platelet antibody data. Among 38 patients, 33 (87%) demonstrated increased platelet-associated antibody or complement at the time of study. 28 patients had elevated IgG; of these patients, three also showed elevated IgM and another six had elevated C3. Five patients had raised levels of IgM or C3 alone. There was a significant inverse correlation (r = -0.6; P < 0.001) between autologous platelet-associated IgG and the log platelet count (data not shown). Because our data suggested a direct relationship between platelet production and platelet count (Fig.  4) , we examined the relationship of platelet turnover (or production) with platelet-associated IgG levels (Fig. 6 ). There was an inverse correlation between log platelet turnover and plateletassociated IgG levels (r = -0.65; P < 0.001). Thus, high levels of platelet-associated antibody were associated with low platelet turnover and low platelet counts. In contrast, there was no relationship between platelet-associated IgG and platelet survival (r = -0.25; P > 0.10) (data not shown).
Homologous platelet survival and turnover studies. The unexpectedly prolonged survival of radiolabeled autologous platelets observed in our prospectively studied patients led us to review a series ofhomologous platelet survival measurements previously performed in a group of 13 AITP patients (Table V) . Some of these patients also had autologous platelet survival measurements. These patients met the same diagnostic criteria as the prospectively studied patients, and none had been previously pregnant or transfused. All Four patients (10-13) ( Table V) had both homologous and autologous platelet survivals performed on the same therapy at relatively constant platelet counts within a 14-d period. For patient 13, the donor was an identical twin. The homologous platelet survivals were significantly shorter than the autologous (1.5 d±l.0 vs. 3.6 d±l.4, respectively, P < 0.01) and corresponding turnovers were greater (70±46 X 109 platelets/liter per d vs. 42±49 X 109 platelets/liter per d, respectively, P < 0.025).
Discussion
This study was performed to elucidate mechanisms of thrombocytopenia in AITP. We used in vitro colony-forming assays to examine the hematopoietic progenitor cell response in AITP, while autologous platelet turnover studies provided an indirect measure of platelet production.
There was no significant difference in CFU-Meg frequency between the AITP treatment groups and normal controls. This finding is in accord with animal studies in which marrow CFUMeg numbers showed little change in response to thrombocytopenia induced by antiplatelet serum (39, 40) Overall, 30% of the AITP patients showed decreased platelet production, 43% had production rates within the normal range, and 27% had increased platelet production. Furthermore, we showed a direct correlation between platelet count and platelet turnover (P < 0.001). Of interest is the comparison ofthe turnover results between the untreated and the prednisone-treated groups. A significantly greater proportion of untreated patients exhibited inappropriately low platelet turnovers (41%) compared to the prednisone group (13%), although the mean survivals for the untreated group (3.3 d± 1.7) and the prednisone groups (3.3 d± 1.5) were essentially identical. Although comparisons between treatment groups must be interpreted with caution, these results suggest that although platelet survival is shortened in AITP and clearly influences the severity of the disease, a more significant factor in determining the platelet count is the rate of effective platelet production that may be improved by prednisone treatment.
In previous studies, estimated rates of platelet production based on either platelet turnover measurements or megakaryocyte quantitation (4, 5) were increased. Our reduced platelet
Mechanisms of Thrombocytopenia in Autoimmune Thrombocytopenia 37 The relationship of the platelet production/clearance index to the platelet count underlines the importance of both rates of platelet production and platelet removal in determining the final platelet count. Comparison of treatment groups suggests that prednisone increases the platelet count by improving platelet production with no significant effect on spleen-liver clearance. To determine whether this is a valid observation requires analysis ofpatients studied in a serial fashion both before and after treatment with prednisone. Such studies are ongoing. However, three patients in this study were analyzed on no treatment and then subsequently on prednisone. All three doubled their platelet turnover rates on prednisone whereas total RE clearance showed no significant change in one and actually increased in two patients (data not shown).
The In summary, megakaryocyte progenitors in AITP show increased cell cycle activity in response to peripheral thrombocytopenia. As megakaryocytes are generally increased in this disorder, the antibody-mediated decreases in platelet production we observed in many AITP patients must occur at or beyond the level of the mature megakaryocyte. We postulate that the ultimate effect ofthe antibody is to prevent newly formed platelets from entering the circulation. However, the circulating platelet count represents a combined response to platelet production as well as sequestration. Steroids and splenectomy variably influence the production/clearance rate to improve platelet count. Further studies are needed to clearly delineate the role of platelet production in this disorder, how the autoantibody impairs platelet production, and the specific mechanisms whereby treatments are effective in individual patients.
